Literature DB >> 26277636

Soluble ST2 and galectin-3 in pediatric patients without heart failure.

Jeffrey W Meeusen1, Jonathan N Johnson2, Amber Gray3, Patricia Wendt3, John L Jefferies4, Allan S Jaffe5, Leslie J Donato3, Amy K Saenger3.   

Abstract

OBJECTIVES: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. DESIGN AND METHODS: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA.
RESULTS: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3.
CONCLUSIONS: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cardiomyopathy; Natriuretic peptides; Reference range

Mesh:

Substances:

Year:  2015        PMID: 26277636     DOI: 10.1016/j.clinbiochem.2015.08.007

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  20 in total

1.  Elevated serum vascular endothelial growth factor and development of cardiac allograft vasculopathy in children.

Authors:  Kae Watanabe; Anis Karimpour-Fard; Alix Michael; Shelley D Miyamoto; Stephanie J Nakano
Journal:  J Heart Lung Transplant       Date:  2018-04-30       Impact factor: 10.247

2.  Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery.

Authors:  Devin M Parker; Allen D Everett; Meagan E Stabler; Luca Vricella; Marshall L Jacobs; Jeffrey P Jacobs; Heather Thiessen-Philbrook; Chirag R Parikh; Jeremiah R Brown
Journal:  J Card Surg       Date:  2019-04-03       Impact factor: 1.620

3.  Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.

Authors:  Julia Anderson; Haeri Seol; Heather Gordish-Dressman; Yetrib Hathout; Christopher F Spurney
Journal:  Pediatr Cardiol       Date:  2017-08-18       Impact factor: 1.655

4.  Novel Biomarkers Improve Prediction of 365-Day Readmission After Pediatric Congenital Heart Surgery.

Authors:  Devin M Parker; Allen D Everett; Meagan E Stabler; Luca Vricella; Marshall L Jacobs; Jeffrey P Jacobs; Chirag R Parikh; Sara K Pasquali; Jeremiah R Brown
Journal:  Ann Thorac Surg       Date:  2019-07-16       Impact factor: 4.330

5.  Evaluation of galectin-3 and intestinal fatty acid binding protein as serum biomarkers in autosomal recessive polycystic kidney disease.

Authors:  Lindsay T Fleischer; Lance Ballester; Mohini Dutt; Kathryn Howarth; Laura Poznick; Kassa Darge; Susan L Furth; Erum A Hartung
Journal:  J Nephrol       Date:  2022-08-18       Impact factor: 4.393

Review 6.  Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications.

Authors:  Emily S Lau; Aleksandra Binek; Sarah J Parker; Svati H Shah; Markella V Zanni; Jennifer E Van Eyk; Jennifer E Ho
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

7.  Biomarkers improve prediction of 30-day unplanned readmission or mortality after paediatric congenital heart surgery.

Authors:  Jeremiah R Brown; Meagan E Stabler; Devin M Parker; Luca Vricella; Sara Pasquali; JoAnna K Leyenaar; Andrew R Bohm; Todd MacKenzie; Chirag Parikh; Marshall L Jacobs; Jeffrey P Jacobs; Allen D Everett
Journal:  Cardiol Young       Date:  2019-07-10       Impact factor: 1.093

8.  Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure.

Authors:  Giuseppe Vergaro; Francesco Gentile; Alberto Aimo; James L Januzzi; A Mark Richards; Carolyn S P Lam; Rudolf A de Boer; Laura M G Meems; Roberto Latini; Lidia Staszewsky; Inder S Anand; Jay N Cohn; Thor Ueland; Lars Gullestad; Pål Aukrust; Hans-Peter Brunner-La Rocca; Antoni Bayes-Genis; Josep Lupón; Akiomi Yoshihisa; Yasuchika Takeishi; Michael Egstrup; Ida Gustafsson; Hanna K Gaggin; Kai M Eggers; Kurt Huber; Greg D Gamble; Lieng H Ling; Kui Toh Gerard Leong; Poh Shuah Daniel Yeo; Hean Yee Ong; Fazlur Jaufeerally; Tze P Ng; Richard Troughton; Robert N Doughty; Gerry Devlin; Mayanna Lund; Alberto Giannoni; Claudio Passino; Michele Emdin
Journal:  ESC Heart Fail       Date:  2022-05-05

9.  ST2 Predicts Risk of Unplanned Readmission Within 1 Year After Pediatric Congenital Heart Surgery.

Authors:  Devin M Parker; Allen D Everett; Meagan E Stabler; Marshall L Jacobs; Jeffrey P Jacobs; Luca Vricella; Heather Thiessen-Philbrook; Chirag R Parikh; Cedric Manlhiot; Jeremiah R Brown
Journal:  Ann Thorac Surg       Date:  2020-04-01       Impact factor: 4.330

10.  Soluble ST2 and Galectin-3: What We Know and Don't Know Analytically.

Authors:  Thomas Mueller; Benjamin Dieplinger
Journal:  EJIFCC       Date:  2016-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.